Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells
Authors:
- 11 March 2012
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 61 (10) , 1735-1743
Abstract
The CD40 receptor is a member of the tumour necrosis factor receptor family and is widely expressed on various cell types. The antitumour activity of CD40 agonist antibody has been observed in B-cell-derived malignancies, but its activity on ovarian cancer remains unclear. However, in this paper, we first confirmed that the anti-CD40 agonist antibody could inhibit the growth of ovarian cancer cells and induce apoptosis. This study investigated the expression of CD40 by ovarian carcinoma tissues and cell lines, at the same time, we evaluated the effect of a recombinant soluble human CD40L (rshCD40L) and an anti-CD40 agonist antibody on cell growth and apoptosis. Flow cytometry and immunohistochemistry assay demonstrated that CD40 was expressed on ovarian carcinoma cell lines and primary ovarian carcinoma cells derived from ascites, as well as on ovarian carcinoma tissues. The growth inhibition of rshCD40L and the anti-CD40 agonist antibody on ovarian carcinoma cells was examined by MTT assay, and the proportion of apoptotic tumour cells was analysed by flow cytometry and Hoechst staining. Our study showed that CD40 was expressed on all ovarian carcinoma cell lines and was examined in 86.2% (162/188) of ovarian cancer tissue samples, but not in normal ovarian tissues (n = 20). Treatment with rshCD40L or anti-CD40 agonist antibody significantly inhibited ovarian carcinoma cell growth and induced apoptosis. Theses results suggest that CD40 is expressed on ovarian carcinoma cells, moreover, that rshCD40L and anti-CD40 agonist antibody have therapeutic potential to inhibit human ovarian cancer growth.Keywords
This publication has 32 references indexed in Scilit:
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myelomaHaematologica, 2010
- Surgical Stress Promotes Tumor Growth in Ovarian CarcinomaClinical Cancer Research, 2009
- The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinomaBJOG: An International Journal of Obstetrics & Gynaecology, 2009
- Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant MelanomaJournal of Immunotherapy, 2008
- TLR7 and CD40 cooperate in IL‐6 production via enhanced JNK and AP‐1 activationEuropean Journal of Immunology, 2008
- Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiationJournal of Allergy and Clinical Immunology, 2007
- Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell linesGynecologic Oncology, 2007
- Triggering CD40 on endothelial cells contributes to tumor growthJournal of Experimental Medicine, 2006
- Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer PatientsJournal of Immunotherapy, 2006
- Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primatesBritish Journal of Pharmacology, 2006